As of Aug 18
| -0.09 / -2.47%|
The 3 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 13.00, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a +265.17% increase from the last price of 3.56.
The current consensus among 4 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.